finanzen.net
18.04.2019 15:17
Bewerten
(0)

THERILLIA acquires TAVEC Pharmaceutical and moves it to Montreal

DRUCKEN

MONTREAL, April 18, 2019 /CNW Telbec/ - Therillia Development Co., a Montreal-based subsidiary of Sanderling Ventures Canada, an investor in early-stage biotech companies, has acquired TAVEC Pharmaceuticals, the leading therapeutic exosome company and is moving its head office from New York to Montreal. Tavec is an early stage therapeutics company focused on developing the next generation of potent anti-cancer gene therapies using the power of injectable, miRNA loaded exosomes, packets of pinched off membrane which penetrate solid tumors, in particular liver cancers.

Logo: Therillia (CNW Group/Therillia Development Company Inc.)

"We have developed a broad-based technology platform that has all the attributes required for multiple therapeutic applications," says Stephen Gould, Ph.D. who, with Florin Selaru, M.D., are leading researchers in the field of exosomes and liver disease. Both are from Johns Hopkins University.

Created in New York in 2015, Tavec pharmaceuticals received seed funding and has successfully completed pre-clinical studies. It is currently working on developing its filings in Quebec to initiate clinical trials in liver cancers and chronic liver diseases. "We are very excited to be moving this unique technology into the clinic in the near future in Quebec," indicated Dr. Fred Hochberg, one of the founders of TAVEC. Dr. Hochberg has had a distinguished career in medicine at Massachusetts General Hospital in Boston. 

"Montreal offers one of the world's most thriving ecosystems for developing biotech companies, including its globally renowned research institutions, rich pool of experienced drug developers and a cost-effective environment for developing important new therapeutics," said Pierre Beauparlant, Ph.D., Chief Business Officer at Therillia. TAVEC is the eighth portfolio company Sanderling has established in Montreal under Therillia in the past five years.

Using Exosomes to Cure Liver Diseases

Exosomes are small vesicles, ~30–150 nm in diameter, produced by all cells and are a major means of cell-to-cell communication. The pioneering work of Gould, Selaru and Ling Li showed that specific types of these vesicles, prepared from select cell cultures, penetrate the stromal matrix of hepatic carcinomas and accumulate in the liver cancer cells. Moreover, injection of exosomes loaded with therapeutic RNAs has been shown to lead to the functional delivery of these RNAs to and into cancer cells, suppressing cancer in aggressive rodent liver cancer models. Furthermore, TAVEC's proprietary exosome-RNA formulations appear to be effective in models of chronic liver disease, as described by Dr. Gould and Dr. Luke Boulter of Edinburgh University.

"The literature suggests that various forms of RNA can be effective therapeutic agents if they can be appropriately delivered to the needed site. The exosomes from the TAVEC preparations have shown that capability. This gives hope to the multitude of patients suffering from liver cancer," said Dr. Hochberg.

About Therillia

Based in Montreal where it was created in 2013, Therillia Development Co. is a subsidiary of Sanderling Ventures, one of the oldest and most established North American venture firms focused exclusively on biomedical investing. Therillia's mission is to benefit from Québec's exceptional scientific and drug development potential to create medical therapies or medical device assets held by Sanderling portfolio companies. This model of "active management" utilizes the expertise of Therillia's seasoned drug development team and has been successful in advancing multiple projects in a cost-effective manner. For more information, visit https://therillia.com

 

SOURCE Therillia Development Company Inc.

Anzeige
Anzeige
Börse Stuttgart Anlegerclub

Die richtige Strategie für die Börsenkrise

Stecken Sie nicht den Sand in den Kopf, sondern kaufen Sie die richtigen Aktien. Erfahren Sie im aktuellen Anlegermagazin mehr über attraktive Qualitätsaktien und zyklische Aktien
Kostenfrei registrieren und lesen!

Heute im Fokus

DAX geht tiefer ins Wochenende -- Wall Street beendet Tag leichter -- Trump verschiebt Entscheidung über EU-Autozölle -- Fresenius legt große Übernahmen auf Eis -- Pinterest, thyssen, Dürr im Fokus

Unfallermittler: Teslas 'Autopilot' war bei Todescrash eingeschaltet. Arcelor-Aktien erneut sehr schwach - Längste Verlustserie seit 1997. Siemens und Philips anscheinend in Brasilien im Visier des FBI. Juventus Turin trennt sich von Trainer Allegri. Labour erklärt Brexit-Gespräche mit Regierung für gescheitert. Salzgitter, Klöckner, thyssen: Stahlwerte-Aktien schwächeln weiter. Zalando-Aktie unter Druck - UBS skeptisch mit Blick auf Wachstum.

Die 5 beliebtesten Top-Rankings

Diese Aktien hat Warren Buffett im Depot
Die Änderungen unter den Top-Positionen
Die erfolgreichsten Kinofilme der letzten 25 Jahre
Welche Titel knackten die Milliardenmarke an den Kinokassen?
In diesen Berufen bekommt man das höchste Gehalt
Mit welchem Beruf kommt man am ehesten an die Spitze?
Städte für Millionäre
Hier fühlen sich die Vermögenden am wohlsten
In diesen Ländern ist Netflix am billigsten
Wo zahlen Abonnenten am wenigsten?
mehr Top Rankings

Umfrage

Bundesjustizministerin Barley (SPD) hat vorgeschlagen, die Mietpreisbremse zu verschärfen. Was halten Sie von dieser Idee?

Online Brokerage über finanzen.net

finanzen.net Brokerage
Handeln Sie für nur 5 Euro Orderprovision* pro Trade aus der Informationswelt von finanzen.net!

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Öl
Euro US-Dollar
Bitcoin
Goldpreis
Meistgesucht
Deutsche Bank AG514000
Scout24 AGA12DM8
Daimler AG710000
Apple Inc.865985
Amazon906866
Wirecard AG747206
TeslaA1CX3T
Allianz840400
BMW AG519000
SAP SE716460
E.ON SEENAG99
BayerBAY001
CommerzbankCBK100
NEL ASAA0B733
BASFBASF11